Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 3
1985 3
1986 2
1987 1
1993 1
1994 1
1995 1
2001 1
2002 1
2004 2
2006 1
2007 1
2008 4
2009 1
2010 1
2011 2
2012 2
2013 2
2014 1
2015 2
2016 11
2017 10
2018 8
2019 6
2020 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
The Multiple Sclerosis Care Unit.
Soelberg Sorensen P, Giovannoni G, Montalban X, Thalheim C, Zaratin P, Comi G. Soelberg Sorensen P, et al. Mult Scler. 2019 Apr;25(5):627-636. doi: 10.1177/1352458518807082. Epub 2018 Oct 23. Mult Scler. 2019. PMID: 30351211 Free PMC article. Review.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. Among authors: soelberg sorensen p. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
Editorial.
Hillert J, Soelberg Sørensen P. Hillert J, et al. Among authors: soelberg sorensen p. J Neurol. 2008 Mar;255 Suppl 1:1-2. doi: 10.1007/s00415-008-1001-9. J Neurol. 2008. PMID: 18317670 No abstract available.
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P. Giovannoni G, et al. Among authors: soelberg sorensen p. Mult Scler. 2018 Oct;24(12):1594-1604. doi: 10.1177/1352458517727603. Epub 2017 Sep 5. Mult Scler. 2018. PMID: 28870107 Free article. Clinical Trial.
Defining active progressive multiple sclerosis.
Sellebjerg F, Börnsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, Hjermind LE, von Essen M, Ratzer RL, Soelberg Sørensen P, Romme Christensen J. Sellebjerg F, et al. Among authors: soelberg sorensen p. Mult Scler. 2017 Nov;23(13):1727-1735. doi: 10.1177/1352458517726592. Epub 2017 Aug 23. Mult Scler. 2017. PMID: 28831853
58 results